Sarcoidosis: patient treatment priorities

Sarcoidosis is a rare disease with the number of patients in the European Union (28 member states), Norway, Iceland and Lichtenstein estimated as ∼102 000 [1, 2]. Some 40% of individuals experience sarcoidosis as a chronic condition, while >60% of individuals find that the disease resolves within...

Full description

Bibliographic Details
Published in:ERJ Open Research
Main Authors: Baughman, Robert P., Barriuso, Rita, Beyer, Kelli, Boyd, Jeanette, Hochreiter, Johann, Knoet, Chris, Martone, Filippo, Quadder, Bernd, Richardson, Jack, Spitzer, Ginger, Valeyre, Dominique, Ziosi, Gianluca
Format: Text
Language:English
Published: European Respiratory Society 2018
Subjects:
Original Research Letters
Norway
Iceland
Online Access:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302206/
https://doi.org/10.1183/23120541.00141-2018
Description
Summary:Sarcoidosis is a rare disease with the number of patients in the European Union (28 member states), Norway, Iceland and Lichtenstein estimated as ∼102 000 [1, 2]. Some 40% of individuals experience sarcoidosis as a chronic condition, while >60% of individuals find that the disease resolves within 2–5 years [3]. However, it has been shown that patients can still have symptoms that result in a reduced quality of life (QoL) even after clinical signs of disease have disappeared. These symptoms include fatigue, pain, everyday cognitive failure, small fibre neuropathy, exercise limitation and depressive symptoms [4, 5]. Findings from a recent survey of patients and their partners in the Netherlands also showed that sarcoidosis has a significant impact on their lives [6].

Similar Items